Nothing Special   »   [go: up one dir, main page]

PT3231801T - Sal de bipirazole como inibidor da jak - Google Patents

Sal de bipirazole como inibidor da jak

Info

Publication number
PT3231801T
PT3231801T PT17158350T PT17158350T PT3231801T PT 3231801 T PT3231801 T PT 3231801T PT 17158350 T PT17158350 T PT 17158350T PT 17158350 T PT17158350 T PT 17158350T PT 3231801 T PT3231801 T PT 3231801T
Authority
PT
Portugal
Prior art keywords
bipyrazole
salt
jak inhibitor
jak
inhibitor
Prior art date
Application number
PT17158350T
Other languages
English (en)
Inventor
Zhuo Jincong
Qian Ding-Quan
Li Yun-Long
Li Qun
Cao Ganfeng
Mei Song
Pan Yongchun
Jia Zhongjiang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PT3231801T publication Critical patent/PT3231801T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT17158350T 2013-05-17 2014-05-16 Sal de bipirazole como inibidor da jak PT3231801T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
PT3231801T true PT3231801T (pt) 2019-05-24

Family

ID=50983151

Family Applications (4)

Application Number Title Priority Date Filing Date
PT147327050T PT2997023T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak
PT182156711T PT3527263T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak
PT17158350T PT3231801T (pt) 2013-05-17 2014-05-16 Sal de bipirazole como inibidor da jak
PT202015939T PT3786162T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT147327050T PT2997023T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak
PT182156711T PT3527263T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT202015939T PT3786162T (pt) 2013-05-17 2014-05-16 Derivados de bipirazole como inibidores da jak

Country Status (36)

Country Link
US (7) US9382231B2 (pt)
EP (5) EP3786162B1 (pt)
JP (5) JP6415543B2 (pt)
KR (4) KR102729910B1 (pt)
CN (2) CN105452239B (pt)
AR (2) AR096330A1 (pt)
AU (5) AU2014265279B2 (pt)
BR (1) BR112015028501B8 (pt)
CA (1) CA2911536C (pt)
CL (1) CL2015003355A1 (pt)
CR (2) CR20190156A (pt)
CY (3) CY1119105T1 (pt)
DK (3) DK3527263T3 (pt)
EA (2) EA036448B1 (pt)
ES (4) ES2960731T3 (pt)
FI (1) FI3786162T3 (pt)
HK (2) HK1221466A1 (pt)
HR (4) HRP20231048T1 (pt)
HU (4) HUE063817T2 (pt)
IL (4) IL242453B (pt)
LT (4) LT3231801T (pt)
ME (2) ME02763B (pt)
MX (2) MX2015015738A (pt)
MY (1) MY174788A (pt)
PE (2) PE20200527A1 (pt)
PH (2) PH12015502563B1 (pt)
PL (4) PL2997023T3 (pt)
PT (4) PT2997023T (pt)
RS (4) RS64591B1 (pt)
SG (2) SG10201709469SA (pt)
SI (4) SI3231801T1 (pt)
SM (4) SMT202100040T1 (pt)
TR (1) TR201905814T4 (pt)
TW (4) TWI840646B (pt)
UA (1) UA117830C2 (pt)
WO (1) WO2014186706A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SMT201800137T1 (it) 2010-03-10 2018-07-17 Incyte Holdings Corp Derivati di piperidin-4-il azetidina come inibitori di jak1
KR101921466B1 (ko) 2010-05-21 2018-11-26 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR101982475B1 (ko) 2011-09-02 2019-05-27 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
SI3231801T1 (sl) 2013-05-17 2019-05-31 Incyte Corporation Bipirazolna sol kot inhibitor JAK
TWI822248B (zh) 2013-08-07 2023-11-11 美商英塞特控股公司 Jak1抑制劑之持續釋放劑型
SI3110409T1 (sl) * 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
SG10201912229XA (en) 2014-04-08 2020-02-27 Incyte Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
KR20240132104A (ko) 2015-02-27 2024-09-02 인사이트 홀딩스 코포레이션 Pi3k 억제제의 염 및 이의 제조 공정
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
ES2995198T3 (en) 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
EP3510030B1 (en) * 2016-09-06 2023-03-22 F. Hoffmann-La Roche AG 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
PE20210169A1 (es) 2017-10-18 2021-01-29 Incyte Corp Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
UA127519C2 (uk) 2018-02-16 2023-09-20 Інсайт Корпорейшн Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами
AU2019245420B2 (en) * 2018-03-30 2024-10-10 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN112567247A (zh) * 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
SMT202400144T1 (it) 2018-09-05 2024-05-14 Incyte Corp Forme cristalline di un inibitore di fosfoinositide 3-chinasi (pi3k)
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
MA54544A (fr) 2018-12-19 2021-10-27 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
SMT202400509T1 (it) * 2020-06-02 2025-01-14 Incyte Corp Procedimenti di preparazione di un inibitore di jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202212341A (zh) 2020-08-18 2022-04-01 美商英塞特公司 製備ｊａｋ１抑制劑之方法及中間體
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
CA3204186A1 (en) 2020-12-04 2022-06-09 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases
KR20230118118A (ko) * 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제
CN112933095A (zh) * 2020-12-29 2021-06-11 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
MX2023008141A (es) 2021-01-11 2023-10-20 Incyte Corp Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
JP2024516302A (ja) 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹を治療するためのｊａｋ１経路阻害薬
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
TW202419088A (zh) 2022-08-05 2024-05-16 美商英塞特公司 使用ｊａｋ抑制劑之蕁麻疹治療
US20240307353A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
NZ531378A (en) 2001-09-19 2006-11-30 Aventis Pharma S Indolizines as kinase protein inhibitors suitable for treating solid tumours
KR20090087139A (ko) 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US8309718B2 (en) * 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
KR101240882B1 (ko) * 2008-03-11 2013-03-11 인사이트 코포레이션 Ｊａｋ 억제제로서의 아제티딘 및 시클로부탄 유도체
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EA025520B1 (ru) * 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
JP5858434B2 (ja) 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
SMT201800137T1 (it) 2010-03-10 2018-07-17 Incyte Holdings Corp Derivati di piperidin-4-il azetidina come inibitori di jak1
CN102985424B (zh) 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
KR101921466B1 (ko) 2010-05-21 2018-11-26 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
SG192910A1 (en) 2011-02-24 2013-09-30 Massachusetts Inst Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2758389B1 (en) 2011-09-22 2017-06-07 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
US9193733B2 (en) * 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
SI3231801T1 (sl) * 2013-05-17 2019-05-31 Incyte Corporation Bipirazolna sol kot inhibitor JAK
TWI822248B (zh) 2013-08-07 2023-11-11 美商英塞特控股公司 Jak1抑制劑之持續釋放劑型
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
TWI693215B (zh) 2014-12-16 2020-05-11 瑞士商諾華公司 作為ｌｐｘｃ抑制劑之異唑異羥肟酸化合物
SMT202400509T1 (it) 2020-06-02 2025-01-14 Incyte Corp Procedimenti di preparazione di un inibitore di jak1
CA3204186A1 (en) 2020-12-04 2022-06-09 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases

Also Published As

Publication number Publication date
TW201512191A (zh) 2015-04-01
EP3231801A1 (en) 2017-10-18
SMT201700258T1 (it) 2017-07-18
AU2022263454B2 (en) 2024-01-18
HUE053122T2 (hu) 2021-06-28
JP6775560B2 (ja) 2020-10-28
EP3527263B1 (en) 2020-10-28
KR20220127371A (ko) 2022-09-19
US9382231B2 (en) 2016-07-05
ES2960731T3 (es) 2024-03-06
CY1121763T1 (el) 2020-07-31
EA036448B1 (ru) 2020-11-11
CN105452239B (zh) 2017-11-21
EP2997023A1 (en) 2016-03-23
FI3786162T3 (fi) 2023-10-02
US11591318B2 (en) 2023-02-28
ES2845210T3 (es) 2021-07-26
TW201940479A (zh) 2019-10-16
JP2016519147A (ja) 2016-06-30
JP7126741B2 (ja) 2022-08-29
PL3786162T3 (pl) 2024-04-08
HK1245769B (zh) 2020-02-07
HRP20190713T1 (hr) 2019-06-14
HUE043573T2 (hu) 2019-08-28
MX2020004506A (es) 2021-08-09
HUE063817T2 (hu) 2024-01-28
PH12015502563B1 (en) 2019-04-26
RS61482B1 (sr) 2021-03-31
SI3231801T1 (sl) 2019-05-31
JP6415543B2 (ja) 2018-10-31
SMT202300352T1 (it) 2024-01-10
PE20200527A1 (es) 2020-03-09
AR096330A1 (es) 2015-12-23
PH12015502563A1 (en) 2016-02-22
US20180312492A1 (en) 2018-11-01
SMT202100040T1 (it) 2021-03-15
TWI840646B (zh) 2024-05-01
ES2720073T3 (es) 2019-07-17
AR118120A2 (es) 2021-09-22
MY174788A (en) 2020-05-14
US9926301B2 (en) 2018-03-27
IL264409B (en) 2021-05-31
BR112015028501B8 (pt) 2023-01-24
NZ753637A (en) 2020-11-27
IL282644B (en) 2021-10-31
US20140343030A1 (en) 2014-11-20
US20200010456A1 (en) 2020-01-09
SG10201709469SA (en) 2017-12-28
RS64591B1 (sr) 2023-10-31
CA2911536A1 (en) 2014-11-20
US11905275B2 (en) 2024-02-20
EP4275756A2 (en) 2023-11-15
CR20190156A (es) 2019-05-16
RS58743B1 (sr) 2019-06-28
BR112015028501A2 (pt) 2017-07-25
TW202116320A (zh) 2021-05-01
TWI664176B (zh) 2019-07-01
CN107698569B (zh) 2020-11-27
CN107698569A (zh) 2018-02-16
EP4275756A3 (en) 2024-02-07
EA202090291A3 (ru) 2020-06-30
KR20240063187A (ko) 2024-05-10
IL282644A (en) 2021-06-30
PT3527263T (pt) 2021-02-01
BR112015028501B1 (pt) 2022-11-01
CA2911536C (en) 2021-07-20
RS56012B1 (sr) 2017-09-29
PL2997023T3 (pl) 2017-08-31
CN105452239A (zh) 2016-03-30
AU2018223058A1 (en) 2018-09-20
EP3786162B1 (en) 2023-08-09
US11001571B2 (en) 2021-05-11
KR102729910B1 (ko) 2024-11-15
SG11201509180WA (en) 2015-12-30
IL242453B (en) 2019-11-28
IL264409A (en) 2019-02-28
HK1221466A1 (zh) 2017-06-02
EP2997023B9 (en) 2018-06-13
ES2626793T3 (es) 2017-07-26
KR20210120120A (ko) 2021-10-06
PH12018502125A1 (en) 2019-03-25
EP3527263A1 (en) 2019-08-21
AU2020202000A1 (en) 2020-04-09
NZ713999A (en) 2020-11-27
SI2997023T1 (sl) 2017-07-31
SI3527263T1 (sl) 2021-05-31
CL2015003355A1 (es) 2016-05-27
JP2019011364A (ja) 2019-01-24
AU2021202685B2 (en) 2022-11-17
HRP20231048T1 (hr) 2023-12-22
US20210238168A1 (en) 2021-08-05
KR102663357B1 (ko) 2024-05-14
US20160289215A1 (en) 2016-10-06
SMT201900223T1 (it) 2019-07-11
MX2015015738A (es) 2016-03-16
AU2021202685A1 (en) 2021-05-27
ME02763B (me) 2018-01-20
EA202090291A2 (ru) 2020-05-31
LT3527263T (lt) 2021-05-10
HRP20170795T1 (hr) 2017-08-25
TWI719401B (zh) 2021-02-21
ME03355B (me) 2019-10-20
WO2014186706A1 (en) 2014-11-20
NZ753638A (en) 2020-11-27
CY1119105T1 (el) 2018-02-14
PE20160126A1 (es) 2016-02-24
IL287313B (en) 2022-03-01
JP2024105557A (ja) 2024-08-06
EP2997023B1 (en) 2017-03-22
JP2022163162A (ja) 2022-10-25
TR201905814T4 (tr) 2019-05-21
EA039660B1 (ru) 2022-02-24
EP3786162A1 (en) 2021-03-03
NZ753636A (en) 2020-11-27
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
SI3786162T1 (sl) 2024-02-29
HRP20210119T1 (hr) 2021-03-05
UA117830C2 (uk) 2018-10-10
LT3231801T (lt) 2019-08-12
HUE033587T2 (hu) 2017-12-28
US20230159501A1 (en) 2023-05-25
PT3786162T (pt) 2023-10-20
CY1123756T1 (el) 2022-05-27
KR20160019905A (ko) 2016-02-22
LT2997023T (lt) 2017-06-26
PT2997023T (pt) 2017-05-31
CR20150633A (es) 2016-04-05
KR102442747B1 (ko) 2022-09-14
US20240150327A1 (en) 2024-05-09
EA201592199A1 (ru) 2016-05-31
AU2014265279B2 (en) 2018-09-27
AU2020202000B2 (en) 2021-03-11
PL3527263T3 (pl) 2021-05-17
AU2014265279A1 (en) 2015-11-26
AU2018223058B2 (en) 2020-01-02
JP2021008493A (ja) 2021-01-28
DK3231801T3 (en) 2019-04-15
NZ753639A (en) 2020-11-27
AU2022263454A1 (en) 2022-12-08
US10435392B2 (en) 2019-10-08
KR102341908B1 (ko) 2021-12-23
DK3786162T3 (da) 2023-10-09
TW202432140A (zh) 2024-08-16
DK3527263T3 (da) 2021-01-25
EP3231801B1 (en) 2019-02-13
IL287313A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
HK1245769B (zh) 作為jak抑制劑的聯吡唑鹽
HK1216531A1 (zh) 新的抑制劑
GB201304526D0 (en) New compounds
GB201317609D0 (en) Inhibitor compounds
ZA201506296B (en) 2-acylaminothiazole derivative or salt thereof
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
IL245452A0 (en) Salts of Armachol
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201304780D0 (en) New compounds